.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Fish and Richardson
Colorcon
Citi
Healthtrust
Harvard Business School
Daiichi Sankyo
Deloitte
Argus Health
US Department of Justice

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019090

« Back to Dashboard

NDA 019090 describes ZANTAC, which is a drug marketed by Teligent, Glaxo Grp Ltd, Glaxosmithkline, and Sanofi Us, and is included in nine NDAs. It is available from one supplier. Additional details are available on the ZANTAC profile page.

The generic ingredient in ZANTAC is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. One hundred and thirty-nine suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

Summary for 019090

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 019090

Suppliers and Packaging for NDA: 019090

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZANTAC ranitidine hydrochloride INJECTABLE;INJECTION 019090 NDA Teligent Pharma, Inc. 52565-096 52565-096-01 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (52565-096-01) > 40 mL in 1 VIAL, PHARMACY BULK PACKAGE
ZANTAC ranitidine hydrochloride INJECTABLE;INJECTION 019090 NDA Teligent Pharma, Inc. 52565-101 52565-101-01 10 VIAL in 1 CARTON (52565-101-01) > 2 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 25MG BASE/ML
Approval Date:Oct 19, 1984TE:APRLD:Yes

Expired Orange Book Patents for NDA: 019090

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
TeligentZANTACranitidine hydrochlorideINJECTABLE;INJECTION019090-001Oct 19, 1984► Subscribe► Subscribe
TeligentZANTACranitidine hydrochlorideINJECTABLE;INJECTION019090-001Oct 19, 1984► Subscribe► Subscribe
TeligentZANTACranitidine hydrochlorideINJECTABLE;INJECTION019090-001Oct 19, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Medtronic
Express Scripts
Harvard Business School
Healthtrust
Accenture
McKesson
Cerilliant
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot